Unibest

Pharmaceutical intermediates

Luseogliflozin Intermediates

2 pharmaceutical intermediates for Luseogliflozin. Indication: Diabetes Mellitus, Type 2.

Submit a ProjectAll intermediates

About Luseogliflozin

Originator
Taiho Pharmaceutical Co., Ltd.
Indication
Diabetes Mellitus, Type 2
Approved Date
03/24/2014

Available intermediates

2 intermediates currently listed for Luseogliflozin. Request specifications, documentation or a quotation for any item below.

Luseogliflozin intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1-(4-ethoxybenzyl)-5-iodo-4-methoxy-2-methylbenzene1459754-49-4//
1-Bromo-5-(4-ethoxyphenylmethyl)-2-methoxy-4-methylbenzene898538-39-1//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Luseogliflozin?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →